Jorge Di Paola
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Jorge Di Paola has a total of 430 co-authors. Here are the top co-authors by number of shared publications:
- Katrina J. Ashworth
Washington University School of Medicine, St. Louis, Missouri, United States
5 shared publications - Brian Re Branchford
Division of Hematology, Department of Pediatrics, Medical College of Wisconsin, Wauwatosa, WI
4 shared publications - Christopher C. Porter
Aflac Cancer & Blood Disorders Center, Children’s Healthcare of Atlanta and Emory University, Atlanta, Georgia, USA
4 shared publications Christopher J. Ng
Department of Pediatrics, University of Colorado, Children's Hospital Colorado, 12800 East 19th Avenue, Research Center 1 North, MS 8302, Aurora, CO 80111, USA
4 shared publicationsKatrina Ashworth
Department of Pediatrics, Washington University School of Medicine, St. Louis, MO
4 shared publications- Paula James
Department of Medicine, Queen's University, Kingston, Canada
4 shared publications
Latest Publications
- Open Access
TNFα drives platelet hyperreactivity and thromboinflammation through regulation of hematopoietic stem and progenitor cells
TNFα is the primary age-related cytokine responsible for hyperreactive platelet formation. In mouse models, increased TNFα induced abnormal megakaryocyte development and platelet activity. Here, we extend these findings to demonstrate that TNFα drives this thrombotic phenotype through expansion of the hematopoietic stem and progenitor cell (HSPCs) compartment. Using HSPC-specific TNFα receptor labeling and single cell RNA sequencing, we found that TNFα receptors are absent from megakaryocytes and their progenitors (MkPs) indicating that TNFα does not directly act on these cells. Chronic TNFα exposure expanded HSPCs in the bone marrow and extramedullary tissues – and these expanded HSPCs retained functional repopulation capacity. Using species-specificity TNFα receptor activation, we further demonstrate that TNFαR1 signaling is sufficient to induce platelet hyperreactivity independent of HSPC expansion. Unlike emergency hematopoiesis, chronic TNFα promoted megakaryopoiesis through the canonical hematopoietic hierarchy as demonstrated by lineage-tracing studies. Mechanistically, chronic TNFα induced a distinct transcriptional program in single cell RNA sequencing of HSPCs and megakaryocytes. Together, these findings establish that chronic TNFα promotes hyperreactive platelet formation not through direct effects on megakaryocytes or MkPs but by expanding and transcriptionally reprogramming HSPCs, thereby imprinting a TNFα dependent program that persists through megakaryopoiesis and ultimately produces hyperreactive platelets. Key Points: Chronic TNFα exposure drives HSC expansion and myeloid biasing of progenitors. TNFα regulates platelet hyperreactivity by signaling through HSPCs, not Mks.
Open AccessTNFα drives platelet hyperreactivity and thromboinflammation through regulation of hematopoietic stem and progenitor cells
TNFα is the primary age-related cytokine responsible for hyperreactive platelet formation. In mouse models, increased TNFα induced abnormal megakaryocyte development and platelet activity. Here, we extend these findings to demonstrate that TNFα drives this thrombotic phenotype through expansion of the hematopoietic stem and progenitor cell (HSPCs) compartment. Using HSPC-specific TNFα receptor labeling and single cell RNA sequencing, we found that TNFα receptors are absent from megakaryocytes and their progenitors (MkPs) indicating that TNFα does not directly act on these cells. Chronic TNFα exposure expanded HSPCs in the bone marrow and extramedullary tissues – and these expanded HSPCs retained functional repopulation capacity. Using species-specificity TNFα receptor activation, we further demonstrate that TNFαR1 signaling is sufficient to induce platelet hyperreactivity independent of HSPC expansion. Unlike emergency hematopoiesis, chronic TNFα promoted megakaryopoiesis through the canonical hematopoietic hierarchy as demonstrated by lineage-tracing studies. Mechanistically, chronic TNFα induced a distinct transcriptional program in single cell RNA sequencing of HSPCs and megakaryocytes. Together, these findings establish that chronic TNFα promotes hyperreactive platelet formation not through direct effects on megakaryocytes or MkPs but by expanding and transcriptionally reprogramming HSPCs, thereby imprinting a TNFα dependent program that persists through megakaryopoiesis and ultimately produces hyperreactive platelets. Key Points: Chronic TNFα exposure drives HSC expansion and myeloid biasing of progenitors. TNFα regulates platelet hyperreactivity by signaling through HSPCs, not Mks.
- Open Access
- 14 October 2025
- Published by American Society of Hematology in Blood Advances
- Vol. 9 (19) , 4780-4789
Effect of age on ISTH-BAT scores and low VWF diagnosis in the Zimmerman Program
An essential component of low von Willebrand factor (VWF)/type 1 von Willebrand disease (VWD) diagnosis is to identify patients with an increased bleeding phenotype, as most individuals with VWF levels in the 30 to 50 IU/dL range do not bleed. The International Society on Thrombosis and Haemostasis-bleeding assessment tool (ISTH-BAT), widely used for assessing bleeding severity, has recently been shown to be age dependent. Although age may also influence ISTH-BAT scores in individuals with VWF levels between 30 and 50 IU/dL, and subsequently affect low VWF diagnosis, this relationship has not been investigated. Therefore, we analyzed 325 participants from the Zimmerman Program, of whom 220 (67.7%) had abnormal ISTH-BAT scores, whereas 105 (32.3%) had normal scores. Our analysis demonstrates that age critically influences the likelihood of attaining an abnormal ISTH-BAT score and, consequently, being registered with a formal diagnosis of low VWF/type 1 VWD. For example, children first assessed at ≥10 years, are twice as likely to have an abnormal ISTH-BAT compared with those first investigated at <10 years (P < .001). In addition, the prevalence of abnormal ISTH-BAT scores was significantly higher in women aged ≥44 years (91.8%) compared with women aged 18 to 28 years (66.7%; P = .004). Finally, we demonstrate that the change in abnormal ISTH-BAT threshold at the age of 18 years critically affects low VWF diagnosis, owing to lower rates of abnormal scores in young adults (P = .006). In conclusion, we demonstrate that the likelihood of a low VWF/type 1 VWD diagnosis is influenced by the age at which ISTH-BAT is first assessed in individuals with mild-to-moderately reduced VWF levels.
- 14 October 2025
- Published by American Society of Hematology in Blood Advances
- Vol. 9 (19) , 4780-4789
Open AccessEffect of age on ISTH-BAT scores and low VWF diagnosis in the Zimmerman Program
An essential component of low von Willebrand factor (VWF)/type 1 von Willebrand disease (VWD) diagnosis is to identify patients with an increased bleeding phenotype, as most individuals with VWF levels in the 30 to 50 IU/dL range do not bleed. The International Society on Thrombosis and Haemostasis-bleeding assessment tool (ISTH-BAT), widely used for assessing bleeding severity, has recently been shown to be age dependent. Although age may also influence ISTH-BAT scores in individuals with VWF levels between 30 and 50 IU/dL, and subsequently affect low VWF diagnosis, this relationship has not been investigated. Therefore, we analyzed 325 participants from the Zimmerman Program, of whom 220 (67.7%) had abnormal ISTH-BAT scores, whereas 105 (32.3%) had normal scores. Our analysis demonstrates that age critically influences the likelihood of attaining an abnormal ISTH-BAT score and, consequently, being registered with a formal diagnosis of low VWF/type 1 VWD. For example, children first assessed at ≥10 years, are twice as likely to have an abnormal ISTH-BAT compared with those first investigated at <10 years (P < .001). In addition, the prevalence of abnormal ISTH-BAT scores was significantly higher in women aged ≥44 years (91.8%) compared with women aged 18 to 28 years (66.7%; P = .004). Finally, we demonstrate that the change in abnormal ISTH-BAT threshold at the age of 18 years critically affects low VWF diagnosis, owing to lower rates of abnormal scores in young adults (P = .006). In conclusion, we demonstrate that the likelihood of a low VWF/type 1 VWD diagnosis is influenced by the age at which ISTH-BAT is first assessed in individuals with mild-to-moderately reduced VWF levels.
- Open Access
- 24 June 2024
- Published by Elsevier in Journal of Thrombosis and Haemostasis
- Vol. 22 (10) , 2681-2691
Deletion of tissue factor pathway inhibitor isoform beta or gamma, but not alpha, improves clotting in hemophilic mice
- 24 June 2024
- Published by Elsevier in Journal of Thrombosis and Haemostasis
- Vol. 22 (10) , 2681-2691
Open AccessDeletion of tissue factor pathway inhibitor isoform beta or gamma, but not alpha, improves clotting in hemophilic mice
- Open Access
- 4 April 2024
- Published by American Society of Hematology in Blood
- Vol. 143 (14) , 1414-1424
Type 1 VWD classification revisited: novel insights from combined analysis of the LoVIC and WiN studies
There is significant ongoing debate regarding type 1 von Willebrand disease (VWD) defintion. Previous guidelines recommended patients with von Willebrand factor (VWF) levels <30 IU/dL be diagnosed type 1 VWD, whereas patients with significant bleeding and VWF levels from 30 to 50 IU/dL be diagnosed with low VWF. To elucidate the relationship between type 1 VWD and low VWF in the context of age-induced increases in VWF levels, we combined data sets from 2 national cohort studies: 162 patients with low VWF from the Low VWF in Ireland Cohort (LoVIC) and 403 patients with type 1 VWD from the Willebrand in The Netherlands (WiN) studies. In 47% of type 1 VWD participants, VWF levels remained 50 IU/dL) in 23% of type 1 VWD cases. Crucially, absolute VWF antigen (VWF:Ag) levels and increase of VWF:Ag per year overlapped between low VWF and normalized type 1 VWD participants. Moreover, multiple regression analysis demonstrated that VWF:Ag levels in low VWF and normalized type 1 VWD patients would not have been different had they been diagnosed at the same age (β = 0.00; 95% confidence interval, −0.03 to 0.04). Consistently, no difference was found in the prevalence of VWF sequence variants; factor VIII activity/VWF:Ag or VWF propeptide/VWF:Ag ratios; or desmopressin responses between low VWF and normalized type 1 VWD patients. In conclusion, our findings demonstrate that low VWF does not constitute a discrete clinical or pathological entity. Rather, it is part of an age-dependent type 1 VWD evolving phenotype. Collectively, these data have important implications for future VWD classification criteria.
- 4 April 2024
- Published by American Society of Hematology in Blood
- Vol. 143 (14) , 1414-1424
Open AccessType 1 VWD classification revisited: novel insights from combined analysis of the LoVIC and WiN studies
There is significant ongoing debate regarding type 1 von Willebrand disease (VWD) defintion. Previous guidelines recommended patients with von Willebrand factor (VWF) levels <30 IU/dL be diagnosed type 1 VWD, whereas patients with significant bleeding and VWF levels from 30 to 50 IU/dL be diagnosed with low VWF. To elucidate the relationship between type 1 VWD and low VWF in the context of age-induced increases in VWF levels, we combined data sets from 2 national cohort studies: 162 patients with low VWF from the Low VWF in Ireland Cohort (LoVIC) and 403 patients with type 1 VWD from the Willebrand in The Netherlands (WiN) studies. In 47% of type 1 VWD participants, VWF levels remained 50 IU/dL) in 23% of type 1 VWD cases. Crucially, absolute VWF antigen (VWF:Ag) levels and increase of VWF:Ag per year overlapped between low VWF and normalized type 1 VWD participants. Moreover, multiple regression analysis demonstrated that VWF:Ag levels in low VWF and normalized type 1 VWD patients would not have been different had they been diagnosed at the same age (β = 0.00; 95% confidence interval, −0.03 to 0.04). Consistently, no difference was found in the prevalence of VWF sequence variants; factor VIII activity/VWF:Ag or VWF propeptide/VWF:Ag ratios; or desmopressin responses between low VWF and normalized type 1 VWD patients. In conclusion, our findings demonstrate that low VWF does not constitute a discrete clinical or pathological entity. Rather, it is part of an age-dependent type 1 VWD evolving phenotype. Collectively, these data have important implications for future VWD classification criteria.
- Top Cited PapersOpen Access
- 5 March 2024
- Published by Royal Society of Chemistry (RSC) in Lab on a Chip
- Vol. 24 (7) , 1867-1874
Next generation microfluidics: fulfilling the promise of lab-on-a-chip technologies
In this perspective article, we present the state of the microfluidic field regarding current limitations and propose future directions and new approaches for the field to advance lab-on-a-chip technologies closer to translation and clinical use.
- 5 March 2024
- Published by Royal Society of Chemistry (RSC) in Lab on a Chip
- Vol. 24 (7) , 1867-1874
Top Cited PapersOpen AccessNext generation microfluidics: fulfilling the promise of lab-on-a-chip technologies
In this perspective article, we present the state of the microfluidic field regarding current limitations and propose future directions and new approaches for the field to advance lab-on-a-chip technologies closer to translation and clinical use.
- Top Cited PapersOpen Access
- 1 February 2024
- Published by American Society for Clinical Investigation in Journal of Clinical Investigation
- Vol. 134 (3)
Multiomic profiling reveals metabolic alterations mediating aberrant platelet activity and inflammation in myeloproliferative neoplasms
Platelets from patients with myeloproliferative neoplasms (MPNs) exhibit a hyperreactive phenotype. Here, we found elevated P-selectin exposure and platelet-leukocyte aggregates indicating activation of platelets from essential thrombocythemia (ET) patients. Single-cell RNA-seq analysis of primary samples revealed significant enrichment of transcripts related to platelet activation, mTOR, and oxidative phosphorylation in ET patient platelets. These observations were validated via proteomic profiling. Platelet metabolomics revealed distinct metabolic phenotypes consisting of elevated ATP generation accompanied by increases in the levels of multiple intermediates of the tricarboxylic acid cycle, but lower α-ketoglutarate (α-KG) in MPN patients. Inhibition of PI3K/AKT/mTOR signaling significantly reduced metabolic responses and hyperreactivity in MPN patient platelets, while α-KG supplementation markedly reduced oxygen consumption and ATP generation. Ex vivo incubation of platelets from both MPN patients and Jak2 V617F–knockin mice with α-KG supplementation significantly reduced platelet activation responses. Oral α-KG supplementation of Jak2 V617F mice decreased splenomegaly and reduced hematocrit, monocyte, and platelet counts. Finally, α-KG treatment significantly decreased proinflammatory cytokine secretion from MPN CD14+ monocytes. Our results reveal a previously unrecognized metabolic disorder in conjunction with aberrant PI3K/AKT/mTOR signaling that contributes to platelet hyperreactivity in MPN patients.
- 1 February 2024
- Published by American Society for Clinical Investigation in Journal of Clinical Investigation
- Vol. 134 (3)
Top Cited PapersOpen AccessMultiomic profiling reveals metabolic alterations mediating aberrant platelet activity and inflammation in myeloproliferative neoplasms
Platelets from patients with myeloproliferative neoplasms (MPNs) exhibit a hyperreactive phenotype. Here, we found elevated P-selectin exposure and platelet-leukocyte aggregates indicating activation of platelets from essential thrombocythemia (ET) patients. Single-cell RNA-seq analysis of primary samples revealed significant enrichment of transcripts related to platelet activation, mTOR, and oxidative phosphorylation in ET patient platelets. These observations were validated via proteomic profiling. Platelet metabolomics revealed distinct metabolic phenotypes consisting of elevated ATP generation accompanied by increases in the levels of multiple intermediates of the tricarboxylic acid cycle, but lower α-ketoglutarate (α-KG) in MPN patients. Inhibition of PI3K/AKT/mTOR signaling significantly reduced metabolic responses and hyperreactivity in MPN patient platelets, while α-KG supplementation markedly reduced oxygen consumption and ATP generation. Ex vivo incubation of platelets from both MPN patients and Jak2 V617F–knockin mice with α-KG supplementation significantly reduced platelet activation responses. Oral α-KG supplementation of Jak2 V617F mice decreased splenomegaly and reduced hematocrit, monocyte, and platelet counts. Finally, α-KG treatment significantly decreased proinflammatory cytokine secretion from MPN CD14+ monocytes. Our results reveal a previously unrecognized metabolic disorder in conjunction with aberrant PI3K/AKT/mTOR signaling that contributes to platelet hyperreactivity in MPN patients.
- Open Access
- 17 March 2023
- Published by Springer Nature in Nature Communications
- Vol. 14 (1) , 1
Author Correction: SVEP1 is an endogenous ligand for the orphan receptor PEAR1
- 17 March 2023
- Published by Springer Nature in Nature Communications
- Vol. 14 (1) , 1
Open AccessAuthor Correction: SVEP1 is an endogenous ligand for the orphan receptor PEAR1
- Open Access
- 15 February 2023
- Published by Springer Nature in Nature Communications
- Vol. 14 (1) , 1-18
SVEP1 is an endogenous ligand for the orphan receptor PEAR1
Sushi, von Willebrand factor type A, EGF and pentraxin domain containing 1 (SVEP1) is an extracellular matrix protein that causally promotes vascular disease and associates with platelet reactivity in humans. Here, using a human genomic and proteomic approach, we identify a high affinity, disease-relevant, and potentially targetable interaction between SVEP1 and the orphan receptor Platelet and Endothelial Aggregation Receptor 1 (PEAR1). This interaction promotes PEAR1 phosphorylation and disease associated AKT/mTOR signaling in vascular cells and platelets. Mice lacking SVEP1 have reduced platelet activation, and exogenous SVEP1 induces PEAR1-dependent activation of platelets. SVEP1 and PEAR1 causally and concordantly relate to platelet phenotypes and cardiovascular disease in humans, as determined by Mendelian Randomization. Targeting this receptor-ligand interaction may be a viable therapeutic strategy to treat or prevent cardiovascular and thrombotic disease.
- 15 February 2023
- Published by Springer Nature in Nature Communications
- Vol. 14 (1) , 1-18
Open AccessSVEP1 is an endogenous ligand for the orphan receptor PEAR1
Sushi, von Willebrand factor type A, EGF and pentraxin domain containing 1 (SVEP1) is an extracellular matrix protein that causally promotes vascular disease and associates with platelet reactivity in humans. Here, using a human genomic and proteomic approach, we identify a high affinity, disease-relevant, and potentially targetable interaction between SVEP1 and the orphan receptor Platelet and Endothelial Aggregation Receptor 1 (PEAR1). This interaction promotes PEAR1 phosphorylation and disease associated AKT/mTOR signaling in vascular cells and platelets. Mice lacking SVEP1 have reduced platelet activation, and exogenous SVEP1 induces PEAR1-dependent activation of platelets. SVEP1 and PEAR1 causally and concordantly relate to platelet phenotypes and cardiovascular disease in humans, as determined by Mendelian Randomization. Targeting this receptor-ligand interaction may be a viable therapeutic strategy to treat or prevent cardiovascular and thrombotic disease.
- Open Access
- 15 November 2022
- Published by American Society of Hematology in Blood
- Vol. 140 (Supplement) , 1095-1097
Transcriptional and Metabolic Profiling Reveals Alpha-Ketoglutarate As a Novel Mediator of Aberrant Platelet Activity and Inflammation in Myeloproliferative Neoplasms
Prior studies by our group and others have demonstrated that platelets from patients with myeloproliferative neoplasms (MPNs) exhibit a hyperreactive phenotype.
- 15 November 2022
- Published by American Society of Hematology in Blood
- Vol. 140 (Supplement) , 1095-1097
Open AccessTranscriptional and Metabolic Profiling Reveals Alpha-Ketoglutarate As a Novel Mediator of Aberrant Platelet Activity and Inflammation in Myeloproliferative Neoplasms
Prior studies by our group and others have demonstrated that platelets from patients with myeloproliferative neoplasms (MPNs) exhibit a hyperreactive phenotype.